Related Experiment Video
Updated: May 4, 2026
An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
Comprehensive review of the prognostic value of galectin-3 in heart failure
Elliot Coburn1, William Frishman
1From the *Department of Medicine, New York Presbyterian-Cornell Weill Medical Center, New York, NY; and †New York Medical College, Westchester Medical Center, Valhalla, NY.
Insights
Galectin-3 is not currently recommended as a reliable prognostic biomarker for heart failure (HF) due to insufficient evidence. Further research is needed to explore its potential role in predicting HF patient outcomes.
Area of Science:
- Cardiology
- Biomarker Research
- Clinical Medicine
Background:
- Heart failure (HF) presents a significant challenge in morbidity and mortality, lacking reliable prognostic biomarkers.
- Identifying predictive indicators for HF patients can enhance goal-directed care.
- Galectin-3, an inflammatory peptide, has emerged as a potential biomarker for HF pathophysiology.
Purpose of the Study:
- To evaluate the utility of galectin-3 as a prognostic marker in patients with heart failure.
- To compare the prognostic information provided by galectin-3 against conventional markers like natriuretic peptide and C-reactive protein.
Main Methods:
- A comprehensive review and analysis of recent studies investigating galectin-3's prognostic value in heart failure patients.
- Assessment of existing evidence supporting or refuting galectin-3's role in HF prognosis.
Main Results:
- The current evidence against the routine use of galectin-3 as a prognostic biomarker in heart failure is substantial.
- Many studies examining galectin-3's prognostic potential, whether positive or negative, suffer from small cohort sizes.
- Existing research is insufficient to establish galectin-3 as a reliable predictor of HF outcomes.
Conclusions:
- Galectin-3 is not recommended for routine clinical use as a prognostic biomarker in heart failure at this time.
- The limitations of current studies, particularly small sample sizes, highlight the need for further investigation.
- Additional research is warranted to definitively determine the prognostic value of galectin-3 in heart failure.
Abstract:
Heart failure (HF) is a major cause of morbidity and mortality in the United States; however, reliable biomarkers predicting outcomes of patients suffering from HF are still not available. Finding a prognostic indicator in patients with HF could ultimately help improve the quality of goal-directed care for these patients. A number of recent studies suggest that galectin-3, a peptide that has been repeatedly shown to be elevated in the setting of inflammatory processes, may provide information regarding the pathophysiologic process underlying HF. If this is the case, galectin-3 may independently be able to provide more information regarding prognosis in patients with HF than some of the more conventional indicators currently in use today (ie, natriuretic peptide, C-reactive protein). We analyzed the most recent and comprehensive studies that have looked at the utility of galectin-3 as a prognostic marker in patients with HF. After a thorough review, we found that the evidence against the use of galectin-3 as a prognostic biomarker in HF was too strong to support its routine use in current clinical settings. However, many of the studies, both in support of and in opposition to the prognostic potential of galectin-3, were uniformly limited by undersized cohorts, and thus the need for further exploration is clearly warranted.
Related Concept Videos
01:26Heart Failure III: Clinical Manifestations
01:29Heart Failure II: Pathophysiology
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:17Pathophysiology of Heart Failure
01:27Heart Failure I: Introduction